What Does the Street Think About Moderna, Inc. (MRNA)?

Core Viewpoint - Moderna, Inc. (NASDAQ:MRNA) is highlighted as a promising healthcare stock under $50, with a Hold rating from Morgan Stanley and a price target of $28.00 [1] Group 1: Strategic Collaboration - Moderna announced a strategic collaboration with Recordati on January 29 to advance its investigational therapeutic mRNA-3927 for propionic acidemia through clinical development and commercialization [1][2] - Under the agreement, Moderna will receive an upfront payment of $50 million and up to an additional $110 million in near-term development and regulatory milestones, along with commercial milestones and tiered royalties on net sales [2] - mRNA-3927 is currently in a registrational study that has reached target enrollment, with a potential data readout anticipated in 2026 [2] Group 2: Company Overview - Moderna is a biotech company focused on developing transformative medicines based on messenger RNA (mRNA) [3] - The company's operations are segmented into the United States, Europe, and Rest of World, with a diverse product pipeline that includes prophylactic vaccines, cancer vaccines, and various therapeutic modalities [3]